HIV-Associated Lipodystrophy Treatment Market Size, Share and Trends Analysis to 2031

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global HIV-Associated Lipodystrophy Treatment Market - (by Lipodystrophy Type (Lipoatrophy and Lipoaccumulation), by Therapeutic class (Anabolism Modulators, Insulin Resistance Modulators, Mitochondrial Antioxidants (l-carnitine), and Other), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global HIV-Associated Lipodystrophy Treatment Market is valued at US$ 172.85 Mn in 2022, and it is expected to reach US$ 239.62 Mn by 2031, with a CAGR of 3.8% during the forecast period of 2023-2031.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/2250

HIV-associated lipodystrophy, or simply lipodystrophy, is a condition that affects HIV-positive people. There is decreased subcutaneous fat in the face, buttocks, arms, and legs. Some studies have found that HIV-infected people on antiretroviral drugs are more likely to develop HIV-associated lipodystrophy, albeit inconclusive. The syndrome of HIV-associated lipodystrophy is defined by altered body composition due to antiretroviral therapy. Two separate clinical symptoms may co-occur to form the condition. Redistribution of adipose tissue, or lipodystrophy, can take the form of either aberrant buildup of fat in the central abdomen (central adiposity) or loss located beneath the skin's surface (lipoatrophy), both of which can have profound effects on self-perception and self-esteem. The morbidity that patients may feel as a result of this ailment can be reduced with the help of several treatments that have been identified. This learning activity discusses HIV-associated lipodystrophy, including its diagnosis, treatment, and the importance of a multidisciplinary team approach to patient care. However, the precise reason for this is unknown. Newer HIV medications are safer and less likely to produce lipodystrophy than older HIV medications.

List of Prominent Players in the HIV-associated lipodystrophy treatment market:
• Theratechnologies Inc.
• GlaxoSmithKline plc
• Novelion Therapeutics Inc.
• AstraZeneca plc
• AbbVie Inc.
• Bristol-Myers Squibb
• Amryt Pharmaceuticals, Inc.,
• Fawn Incorporation,
• Abbott Healthcare Solutions,
• Lupin Pharmaceuticals, Inc.,
• Pfizer Inc.,
• Bayer Inc.,
• Novartis Pharmaceuticals Corporation,
• Galderma Laboratories, L.P.
• Others

Market Dynamics:

Drivers-
The growing demand for the HIV-associated lipodystrophy treatment market is fueled because HIV-associated lipodystrophy may have a protective effect on several metabolic parameters, decreasing the likelihood of atherosclerosis and type 2 diabetes. Treatment with ART has been shown to improve the health and well-being of those living with HIV. Suppressing HIV replication in people infected with the virus is another benefit of ART that helps prevent the spread of the infection to others.

Challenges:
The prime challenge is a lack of awareness, a shortage of competent individuals, and a lack of norms and protocols because of lockdowns and isolation in emerging countries, which is predicted to slow the growth of the HIV-associated lipodystrophy treatment market. Lack of drug availability; lack of patient commitment to treatment; existence of co-morbidities and opportunistic infections; absence of a firm foundation for the control programs. Depression, low self-esteem, and social isolation have all been linked to HIV-associated lipodystrophy, which causes severe emotional anguish. As a result of insulin resistance, metabolic problems such as hyperlipidemia and hyperglycemia raise the danger of atherosclerotic cardiovascular disease. Patients with HIV can receive the COVID-19 vaccine without risk. There is no evidence that the COVID-19 vaccine is incompatible with HIV preventative or treatment drugs.

Regional Trends:
The North American HIV-associated lipodystrophy treatment market is anticipated to register a major market share in revenue. It is projected to grow at a high CAGR in the near future because of the reasonable terms of the protection offered by the policy. The HIV medication side effects, including HIV-related lipodystrophy, are now covered by insurance in Massachusetts. Treatments for HIV-related lipodystrophy are expected to do well if this insurance policy is widely adopted. Besides, Europe had a substantial market share because of the alarming rate of HIV infection in the region. The global HIV-associated lipodystrophy Syndrome treatment market is expected to expand steadily because of increasing demand, rising environmental consciousness, and developing technologies.

Curious about this latest version of the report? Enquiry Before Buying: https://www.insightaceanalytic.com/report/hiv-associated-lipodystrophy-treatment-market/2250

Segmentation of HIV-Associated Lipodystrophy Treatment Market-
By lipodystrophy type,
• Lipoatrophy
• Lipoaccumulation

By therapeutic class,
• Anabolism modulators
• Growth hormones
• Anabolic steroids
• Insulin resistance modulators
• Metformins
• Thiazolidinediones
• Mitochondrial antioxidants (l-carnitine)
• Other miscellaneous metabolic agents

By distribution channel,
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Region-
North America-
• The US
• Canada
• Mexico

Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-
• Brazil
• Argentina
• Rest of Latin America

Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/2250

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis of key market insights in a timely and cost-effective manner.

This release was published on openPR.